MNX has started listing futures contracts that let traders bet on the IPO timelines and revenue trajectories of artificial intelligence labs. The contracts provide leveraged exposure to companies that are still private, rather than shares. Settlement is tied to IPO filings, private-market valuations, or revenue estimates.
What MNX is actually offering
The products are futures, not equity. That means buyers don't get ownership, voting rights, or any claim on the AI labs themselves. Instead, they hold a contract whose payout depends on whether a lab files for an IPO, what private investors think it's worth, or what its revenue looks like at a set date. Leverage amplifies both gains and losses, a standard feature of futures but a new wrinkle for people used to trading public tech stocks.
MNX hasn't disclosed which specific AI labs are covered or the exact contract sizes. The company also hasn't said which exchanges will list the futures or when the first contracts will trade. Those details matter because they determine liquidity and who can actually buy in.
Why private AI valuations are hard to pin down
Private-market valuations are notoriously sticky. They come from funding rounds, secondary sales, or internal marks, not from a live order book. An IPO filing is a clearer event, but it can be withdrawn or delayed. Revenue estimates for private AI labs are often based on limited disclosures, and those numbers can shift fast when compute costs or customer contracts change.
That makes settlement a real design challenge. If a contract pays out based on a private valuation, which valuation counts? The last primary round? The most recent secondary trade? An average of several sources? MNX hasn't said. Without a clear rule, traders could end up arguing over a number that was never public in the first place.
The leverage angle
Leverage is the selling point and the risk. A small move in the underlying reference—say, a rumored IPO delay or a leaked revenue figure—can wipe out a position or multiply it. That's normal for futures, but it's a different game than buying shares in a public AI company. There's no dividend, no shareholder vote, and no ability to hold through a downturn unless the contract allows it.
Retail access is another open question. Futures typically trade on regulated exchanges with margin requirements. MNX hasn't said whether these contracts will be available to individual traders or only to institutions. If they're open to retail, expect brokers to add risk disclosures and possibly higher margin requirements.
What comes next
MNX needs to publish contract specifications: the reference entities, settlement dates, and the exact data sources for IPO filings, private valuations, and revenue estimates. Until those are out, the futures are more concept than tradable product. The first listings will show whether traders are willing to bet on private AI companies through a derivative that settles on paperwork and estimates rather than a closing price.
For now, the launch marks another attempt to build a market around AI labs that haven't gone public. Whether it works depends on the fine print—and on whether anyone wants to take the other side of a trade tied to numbers that are hard to verify.
